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CD4+CD25+Foxp3+ regulatoryT cells (Tregs) are essential players in the control of immune
responses. Recently, accordingly to their origin, two main subsets of Tregs have been
described: thymus-derived Tregs (tTregs) and peripherally derived Tregs (pTregs). Numer-
ous signaling pathways including the IL-2/STAT5 or theTGF-β/Smad3 pathways play a crucial
role in segregating the two lineages. Here, we review some of the information existing on
the distinct requirements of IL-2, TGF-β, and TNF-α three major cytokines involved in tTreg
and pTreg generation, homeostasis and function. Today it is clear that signaling via the IL-
2Rβ chain (CD122) common to IL-2 and IL-15 is required for proper differentiation of tTregs
and for tTreg and pTreg survival in the periphery. This notion has led to the development
of promising therapeutic strategies based on low-dose IL-2 administration to boost the
patients’ own Treg compartment and dampen autoimmunity and inflammation. Also, solid
evidence points toTGF-β as the master regulator of pTreg differentiation and homeostasis.
However, therapeutic administration of TGF-β is difficult to implement due to toxicity and
safety issues. Knowledge on the role of TNF-α on the biology of Tregs is fragmentary and
inconsistent between mice and humans. Moreover, emerging results from the clinical use
of TNF-α inhibitors indicate that part of their anti-inflammatory effect may be dependent
on their action on Tregs. Given the profusion of clinical trials testing cytokine administra-
tion or blocking to modulate inflammatory diseases, a better knowledge of the effects of
cytokines on tTregs and pTregs biology is necessary to improve the efficiency of these
immunotherapies.
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Thymus-derived Tregs (tTregs), which emerge from the thymus as
a distinct lineage, and peripherally derived Tregs (pTregs), which
are generated outside the thymus from CD4+CD25− T cell pre-
cursors under particular conditions of stimulation, present great
similarities, and differences. They are both defined by the expres-
sion of the transcription factor Foxp3, widely recognized as the
master regulator of Treg fate. This factor, expressed quite specifi-
cally by Tregs (Fontenot et al., 2003; Hori et al., 2003) is required
for their suppressive function both in vitro and in vivo (Fontenot
et al., 2003, 2005a; Hori et al., 2003). But Tregs’ specific genetic
signature is only partially dependent on Foxp3 (Sugimoto et al.,
2006; Gavin et al., 2007; Hill et al., 2007; Lin et al., 2007; Ohkura
et al., 2012). And, in order to acquire this exclusive signature and
mature into a stable lineage, both tTregs and pTregs will go through
a process of “education” in several steps and different localizations.
Here, we will describe the role of cytokines during this process.
The role of the TCR in Treg development and of cytokines in
Treg effector mechanisms have been the subject of recent excellent
reviews (Vignali et al., 2008; Ohkura et al., 2013) and will not be
extensively discussed here.
THYMIC DERIVED Treg CELLS
tTregs have been defined by the constitutive expression of the high
affinity IL-2Rα chain, CD25 (Sakaguchi et al., 1995). They are
selected in the thymus based on their recognition of self-antigens
by a TCR of high avidity (Jordan et al., 2001) and represent an
important fraction of the total Tregs found in periphery (Hsieh
et al., 2006; Josefowicz et al., 2012a). Removal of the thymus
early after birth leads to various autoimmune symptoms (Itoh
et al., 1999), suggesting that tTregs participate in the continuous
prevention of spontaneous autoimmunity.
IL-2 REGULATES BOTH THYMIC DEVELOPMENT AND PERIPHERAL
HOMEOSTASIS OF tTreg
The role of IL-2 in tTreg differentiation and homeostasis has been
extensively studied. Early work showed that mice deficient for
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IL-2 or CD25 were profoundly deprived of Tregs in the periph-
ery but not in the thymus (D’Cruz and Klein, 2005; Fontenot
et al., 2005b), suggesting that IL-2 was mandatory for Treg home-
ostasis in the periphery but not for thymic generation. However,
mice doubly deficient for IL-2 and IL-15, or for the IL-2Rβ chain
(CD122) common to IL-2 and IL-15, present a quasi-complete
depletion of thymic Treg cells (Burchill et al., 2007; Soper et al.,
2007). Consequently, the CD122 signaling is mandatory for proper
differentiation of tTregs. At the molecular level, binding of the
CD122 signaling intermediate STAT5 to the conserved non-coding
DNA sequence 2 (CNS2) element at the Foxp3 locus is required
for optimal Foxp3 expression (Zorn et al., 2006; Burchill et al.,
2007; Yao et al., 2007; Mouly et al., 2010) (for a recent review
on the role of cytokine-induced transcription factors regulating
Foxp3 expression, see Merkenschlager and von Boehmer, 2010).
Demethylation of the CNS2 is the hallmark of stable Tregs but
the role played by IL-2 in this process appears minimal since IL-2
cannot drive demethylation of the CNS2 in CD25hiFoxp3− tTreg
precursor if applied in the absence of TCR signals (Toker et al.,
2013). Indeed, this precursor population expresses Foxp3 in vitro
upon IL-2 stimulation without requirement for additional TCR
signaling (Lio and Hsieh, 2008). Thus, a two-step model for Treg
differentiation has been proposed in which TCR/CD28 signals
first induce the differentiation of this precursor with enhanced
sensitivity to IL-2/IL-15, followed by direct Foxp3 induction by
IL-2/IL-15 signaling in a STAT5-dependent TCR-independent
manner (Burchill et al., 2008; Lio and Hsieh, 2008). However,
we believe that this two-step model is incomplete. Indeed, we
have recently demonstrated that a minority of tTreg precursors
expressed pSTAT5 ex vivo in unmanipulated neonates and we pro-
pose that this subset might be the direct precursors of pSTAT5+
CD25+Foxp3+ tTregs (Figure 1) (Goldstein et al., 2011). Never-
theless, not all Foxp3+ T cells express pSTAT5, suggesting either
that Foxp3 expression can be maintained without continuous
STAT5 phosphorylation or that differentiation of tTreg may pro-
ceed through a STAT5-independent pathway. Thus, the exact
mechanism by which CD122 signaling controls the generation of
tTregs remains to be determined.
Outside the thymus, the role of IL-2 on Treg homeostasis is
widely accepted: no IL-2, no functional tTregs in the periph-
ery. Results obtained in mice deficient for IL-2 (Sadlack et al.,
1993, 1995) or its receptor (Suzuki et al., 1995; Willerford et al.,
1995), which develop extensive lymphadenopathy and die of sys-
temic auto-immunity early after birth, extended the role of IL-2
from a “T Cell Growth Factor” (Smith et al., 1980) to “the gate-
keeper of immunological tolerance”. The autoimmunity observed
in IL-2/IL-2R KO mice (whether CD25, CD122, or CD132 KO,
the different components of the IL-2R) is associated with a pro-
found deficit in Treg numbers and function, suggesting that tTregs
generated in the absence of IL-2/IL-2R signaling cannot survive
in the periphery. This view has been challenged by others, who
reported the presence of Foxp3+ cells in the periphery of IL-2 KO
mice (Liston et al., 2007). Noteworthy is the lack of autoimmunity
in this later study. Thus, the association between the lack of IL-
2, Treg deficit, and autoimmune manifestations cannot be always
made. In further support of an important role for IL-2 in Treg sur-
vival, in vivo neutralization of IL-2 by the injection of an anti-IL-2
antibody results in the rapid depletion of Tregs and in the appear-
ance of systemic, albeit limited, autoimmunity (Setoguchi et al.,
2005). IL-2 is required for the maintenance of Foxp3 protein and
mRNA expression both in vitro and in vivo (Setoguchi et al., 2005;
Murawski et al., 2006; Passerini et al., 2008; Rubtsov et al., 2010).
Furthermore, Tregs are crucially dependent on paracrine IL-2 pro-
duction by effector T cells (Teffs), as they cannot produce IL-2 due
to direct Foxp3-mediated repression of IL-2 transcription (Wu
et al., 2006). Worth mentioning, the number of Tregs is indexed
to the number of IL-2 producing Teffs (Almeida et al., 2006). In
addition, polymorphisms in IL-2, CD25, or downstream adaptors
FIGURE 1 | A hypothetic model for tTreg differentiation in the thymus. (A)
Immature CD4+ thymocytes are engaged by strong agonist
TCR/co-stimulatory signals, which results in the expression of the IL2R alpha
chain CD25. (B) Subsequent interaction of immature tTreg precursors with
CD122 signaling cytokines IL-2 and IL-15 leads to STAT5 phosphorylation to
generate tTreg precursors. (C) Following continuous engagement of CD122,
Foxp3 expression is induced in tTreg precursors to generate fully mature
tTregs.
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genes are associated with impaired Treg numbers or function and
higher susceptibility to autoimmunity (Bottini et al., 2004; Vella
et al., 2005; Todd et al., 2007; Yamanouchi et al., 2007; Liston et al.,
2008; Sgouroudis et al., 2008, 2011). Indeed, we and others have
shown that IL-2 administration to mice (Tang et al., 2008; Wil-
son et al., 2008; Webster et al., 2009; Grinberg-Bleyer et al., 2010a;
Dinh et al., 2012) and humans (Koreth et al., 2011; Saadoun et al.,
2011) increases Treg numbers, reinforces their suppressive func-
tion, and protects from chronic inflammation. Indeed, low-dose
IL-2 administration to pre-diabetic NOD mice which prevents
disease development, increases Treg proportions specifically in the
pancreas and these IL-2 expanded Tregs express higher levels of
Bcl-2, CD25, and Foxp3, suggestive of increased resistance to apop-
tosis and higher activation (Tang et al., 2008). Furthermore, IL-2
administration to new onset diabetic NOD mice which reverts
hyperglycemia, does not significantly increase Treg frequencies,
yet Tregs express higher levels of molecules associated to Treg
function, such as CD25, Foxp3, GITR, and ICOS and there is a
decreased production of IFN-γ by pancreas infiltrating CD8+ T
cells (Grinberg-Bleyer et al., 2010a). These results suggest that IL-
2-boosted Tregs may have an improved suppressive function. The
demonstration that IL-2 is critical for Treg biology has opened
new perspectives for the treatment of inflammatory diseases.
A MORE UNCERTAIN ROLE FOR TGF-β ON tTreg DEVELOPMENT AND
FUNCTION
The role of TGF-β during tTreg differentiation is controversial.
Mice deficient for TGF-β (Shull et al., 1992; Marie et al., 2005) or
for either one subunit of its receptor (Gorelik and Flavell, 2000;
Leveen et al., 2002; Li et al., 2006; Marie et al., 2006; Liu et al., 2008)
develop a lethal autoimmune syndrome associated with a deficit
in Tregs (Fahlen et al., 2005; Marie et al., 2005, 2006; Almeida et al.,
2006; Li et al., 2006; Liu et al., 2008). Interestingly, this syndrome
is only seen if TGF-β is silenced early in T cell differentiation, sug-
gesting that besides a deficit in tTreg, lymphopenia is an additional
trigger of autoimmunity in the absence of TGF-β signaling (Zhang
and Bevan, 2012). At the molecular level, TGF-β triggers the bind-
ing of Smad3/NFAT complex on the promoter and on the CNS1
enhancer regions of the Foxp3 gene (Tone et al., 2008). However,
mice deficient for CNS1 have no alteration in tTreg differentia-
tion (Zheng et al., 2010), suggesting that TGF-β is not required for
this process. But mice deficient for both TGF-β and IL-2 are com-
pletely deprived of tTregs (Liu et al., 2008), suggesting that TGF-β
might compensate a defect in IL-2 and induce Foxp3 expression.
How and when IL-2 and TGF-β signaling pathways intersect in the
thymus to generate Foxp3+ cells remains to be fully elucidated.
Very few studies have focused on the potential role of TGF-β on
tTreg homeostasis and function. In the previously cited study from
the group of Alexander Rudensky (Marie et al., 2005), the TGF-β1
deficient mice that presented reduced frequencies of CD4+CD25+
cells, also showed reduced Foxp3 expression among these cells. In
addition, Treg deficient for the TGF-βRII showed decreased sup-
pressive function in vitro. However, this early study used total
CD4+CD25+ peripheral cells as Tregs, which contains both tTregs
and pTregs. Thus, it was impossible at the time to exclude that the
effect came from a specific impact of TGF-β on the pTreg sub-
set. More recently, the same group clarified the situation. Indeed,
they showed that tTregs purified from CNS1-deficient mice, which
present altered TGF-β signaling and lack pTreg differentiation
(Zheng et al., 2010; Josefowicz et al., 2012a), did not present altered
suppressive function or decreased Foxp3 expression (Josefowicz
et al., 2012a). Taken together, these studies suggested that TGF-β is
not a main player in tTreg homeostasis or maintenance of Foxp3
expression and suppressive function in these cells.
TNF-α SEEMS TO PARTICIPATE TO tTreg DEVELOPMENT AND HAS A
CONTROVERSIAL ROLE ON tTreg FUNCTION
TNF-α, a pleiotropic cytokine well known for its major role in
the initiation and orchestration of the pro-inflammatory immune
response, may also display anti-inflammatory effects (Jacob and
McDevitt, 1988; Yang et al., 1994). Mechanistically, TNF-α signals
through two different receptors: TNFR-1 and TNFR-2. TNFR-
1 is ubiquitously expressed and can induce apoptosis through
its intracellular death domain. Furthermore, TNF-α signaling
through TNFR-1 under normal conditions leads to activation of
the canonical NF-κB pathway that regulates cell activation and
differentiation (Chen and Goeddel, 2002; Sun, 2011). On the con-
trary, TNFR-2 expression is more restrained. This receptor does
not have an intracellular death domain and rather induces T
cell activation and proliferation (Grell et al., 1998) through the
non-canonical NF-κB pathway (Sun, 2011). Furthermore, TNF-
α receptors are differentially expressed in Teffs and Tregs. In mice
and men, Teff can rapidly upregulate TNFR-2 expression after TCR
stimulation, but at the steady state only a very small proportion of
Teffs expresses TNFR-2 (Valencia et al., 2006; Chen et al., 2007).
In contrast, a significant proportion of Tregs expresses TNFR-2
at the steady state and can further increase its expression upon
TCR stimulation or TNF-α incubation (Valencia et al., 2006; Chen
et al., 2007). Hence, the dichotomic effect of TNF-α has been – at
least in part – attributed to a pro-inflammatory action mediated
by TNFR-1 on Teff cells and an anti-inflammatory effect mediated
by TNFR-2 signaling on Tregs. However, although different bio-
logical functions can be assigned to the signals induced by each of
the two receptors, confounding issues come from the existence of
receptor crosstalk and shared actions, which are dependent on cell
intrinsic and extrinsic factors (Faustman and Davis, 2010).
A likely role for TNF-α on tTreg development comes from
TNFR-2 KO or TNFR-2 ligands-deficient (TNF-α/LT-α/LT-β)
triple KO mice that show a decrease of Tregs in the thymus (Chen
et al., 2013). These results need however to be interpreted with cau-
tion since lymphopenia per se or alterations of the thymic stromal
architecture might affect tTreg generation. Further elucidation of
the role of TNF-α and TNF receptors awaits the generation of mice
with conditional ablation of TNF receptors in the Treg lineage.
Data on the effect of TNF-α on Treg function are fragmented
and sometimes controversial. In vitro, TNF-α through TNFR-2
signaling increases mouse tTreg proliferation in the presence of
IL-2 (Chen et al., 2007) and optimally activates Tregs increas-
ing the expression of receptors of the TNF super family, such as
TNFR-2, 4-1BB, and OX40 (Hamano et al., 2011). In addition,
pre-incubation of Tregs with TNF-α can improve their in vitro
suppressive function (Chen et al., 2007). However, Tregs obtained
from WT or TNFR-2 KO mice appear to have similar in vitro sup-
pressive activity (van Mierlo et al., 2008). Moreover, and at odds
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with mice results, TNF-α seems to reduce Treg suppressive func-
tion in humans (Valencia et al., 2006; Chen et al., 2007; Nagar et al.,
2010; Zanin-Zhorov et al., 2010). The main issue of these exper-
iments is that TNF-α can act on both Treg and Teff populations
and that activated Teffs, which express TNFR-2, are less sensitive
to Treg-mediated suppression (Chen and Oppenheim, 2010).
In vivo, TNF-α seems to contribute to Treg homeostasis (Chen
et al., 2013; Chopra et al., 2013) and one paper implicates TNFR-2
and the non-canonical NF-kB pathway in this action (Rauert et al.,
2010). Also, TNF-α seems to enhance Treg function in vivo, as sug-
gested by our own results showing that activated Teffs can boost
Treg proliferation and suppressive function, partly by a TNF-α-
mediated mechanism probably implying the non-canonical NF-
kB pathway (Grinberg-Bleyer et al., 2010b). Additionally, TNF-α
could improve Treg proliferation and accumulation in mouse
models of cecal ligation puncture, colitis, and cancer (Chen et al.,
2007, 2013; Chopra et al., 2013). Moreover, the fact that TNF-
α−/−LTα−/−LTβ−/− and TNFR-2−/−mice possess less Tregs in the
periphery supports the idea that TNF-α, like IL-2, plays a role in
Treg homeostasis (Chen et al., 2013; Chopra et al., 2013). However,
neither TNF-α−/− nor TNFR-2−/− mice develop spontaneous
autoimmunity and Tregs recovered from these mice express the
same level of Foxp3 (Chen et al., 2013). Nevertheless, as the lack
of TNFR-2 expression on Teffs could impact their pathogenicity,
it is difficult to evaluate the individual contribution of the TNF-
α/TNFR-2 pathway to Treg and Teff function. Interestingly, recent
work using transfer of highly purified WT or TNFR-2 KO Tregs
in RAG−/− mice suggests that colitis suppression could be depen-
dent on TNFR-2 expression by Tregs in vivo (Housley et al., 2011;
Chen et al., 2013). Collectively, these data point to an important
role of signaling though TNFR-2 in the suppressive function of
Tregs in vivo and calls for confirmation with the use of Tregs with
conditional ablation of TNF receptors.
In humans, TNF-α has been implicated in the physiopathology
of autoimmune diseases and consequently anti-TNF-α treatments
(antibodies or soluble receptor) have been used with successful
results obtained in Crohn’s disease and rheumatoid arthritis (Chan
and Carter, 2010). Interestingly, beyond dampening TNF-α’s pro-
inflammatory effect, anti-TNF-α treatment has been associated
with an accumulation of Tregs (Ehrenstein et al., 2004) and with
improved Treg function (Ehrenstein et al., 2004; Valencia et al.,
2006; Nadkarni et al., 2007). Likewise, a recent study showed that
TNF-α present in the synovial fluid of RA patients reduced Treg
suppressive function and this function was restored in anti-TNF-α
treated patients (Nie et al., 2013). However, increased frequencies
of Tregs, could be alternatively explained by a relative reduc-
tion of the activated Foxp3− cells without a direct change in
Treg homeostasis. Indeed, in mice transgenic for human TNF-α,
which develop spontaneous arthritis, both pools of Teffs and Tregs
decrease during the disease course and increase during anti-TNF-
α treatment (Biton et al., 2011). Of note, not all patients respond to
anti-TNF therapies and even some of them paradoxically develop
anti-TNF-induced autoimmune diseases such as multiple sclerosis
(MS), T1D, inflammatory bowel disease, vasculitis, lupus, and
many others (Perez-Alvarez et al., 2013) suggesting that TNF-α
could also have a regulatory role in other human autoimmune
conditions. Although the underlying cause is not yet understood,
some insight for the unexpected role of TNF-α in T1D and MS may
be gained from the corresponding murine models. Indeed, TNF-
α can exacerbate T1D and EAE when administered early during
disease initiation and can inhibit disease progression when admin-
istered at later time points (Ruddle et al., 1990; Willenborg et al.,
1995; Wu et al., 2002). Therefore, it is possible that the opposite
response to anti-TNF therapies originates from the opposite roles
that TNF may have during the different phases of the disease.
PERIPHERALLY DERIVED-REGULATORY T CELLS
The group of J. Lafaille was among the first to described pTregs
in 2002. They showed that the transfer of CD4+ spleen T cells
could prevent EAE in an IL-2-dependent process involving the
differentiation of CD4+CD25+ Tregs from CD4+CD25− T cell
precursors (Furtado et al., 2002). Induced from naïve CD4+ T cells
in the periphery, pTregs present a distinct and broader TCR reper-
toire than tTreg (Haribhai et al., 2011; Josefowicz et al., 2012b).
Indeed, pTreg differentiation mainly occurs in the context of bac-
terial or viral infection (Robertson et al., 2006; Curotto de Lafaille
and Lafaille, 2009; Ertelt et al., 2009), in tumors (Nishikawa et al.,
2003; Liu et al., 2007), or in mucosal tissues notably in a context of
oral tolerance (Mucida et al., 2005; Coombes et al., 2007; Sun et al.,
2007; Josefowicz et al., 2012a). A recent study suggested that pTreg
main function would be the prevention of mucosal Th2-mediated
immunity, notably in the gastrointestinal tract and lungs (Josefow-
icz et al., 2012a). pTregs would also be involved in the induction of
tolerance to commensal microbiota (Sun et al., 2007; Josefowicz
et al., 2012a).
The differentiation of pTregs requires antigenic stimulation in
a defined anti-inflammatory environment, process orchestrated
in part by dendritic cells (DC). Several DC subsets have been
associated with pTreg induction (Yamazaki et al., 2007), includ-
ing plasmacytoid DC (Ochando et al., 2006; Goubier et al., 2008)
and CD103+ DCs, which following education by retinoic acid
(RA) differentiate into tolerogenic DC, mainly in the intestine
(Coombes et al., 2007; Sun et al., 2007). H. Von Boehmer’s group
showed that targeting the antigen toward DCs through DEC205
recognition induced the conversion of CD4+ naïve T cells into
CD4+CD25+Foxp3+ pTreg (Kretschmer et al., 2005). This induc-
tion was shown to be dependent on TGF-β (Yamazaki et al., 2008).
Indeed, mice deficient for TGF-β in Langerhans cells (a special-
ized subset of DC in the skin) develop signs of skin auto immunity
(Kaplan et al.,2007), in agreement with the hypothesis that a lack of
DC in the skin may lead to local auto-immunity due to a defect in
Treg. The role of IL-2 or TNF-α produced by DC in the induction
of pTreg remains to be fully elucidated.
TGF-β IS THE MASTER REGULATOR OF pTreg DIFFERENTIATION AND
HOMEOSTASIS
The differentiation of pTregs from CD4+CD25−Foxp3− naive T
cells requires TGF-β. Initial studies showed that in vitro treatment
of murine or human CD4+CD25−Foxp3− naive T cells with
TGF-β induced Foxp3 expression in these cells and conferred a
suppressive function (Chen et al., 2003; Walker et al., 2003). Then,
a prominent role for TGF-β in pTreg differentiation has been
demonstrated in vivo (Marie et al., 2005, 2006; Coombes et al.,
2007; Sun et al., 2007), notably in the context of oral tolerance
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(Curotto de Lafaille and Lafaille, 2009). In addition, mice defi-
cient for the TGF-β-sensitive CNS1 enhancer do not present any
differentiation of pTregs (Zheng et al., 2010; Josefowicz et al.,
2012a) confirming the essential role of TGF-β in pTreg induction.
Interestingly, in vivo pTregs differentiation by TGF-β can occur
both in physiological (Coombes et al., 2007; Sun et al., 2007) and
pathological (Grainger et al., 2010) situations.
Two kinds of regulators of pTreg differentiation can be distin-
guished. First, those that interfere with TGF-β signaling like TNF-α
(Zhang and Bevan, 2012), or those that induce PI3K signaling. Of
importance, the PI3K/Akt/mTOR pathway is a strong inhibitor
of Foxp3 expression, which prevents both tTreg and pTreg differ-
entiation (Haxhinasto et al., 2008; Sauer et al., 2008). Consistent
with these observations, a very recent study demonstrated that
pTreg differentiation could not occur in presence of the C3a or
C5a signaling pathway. This pathway blocks Foxp3 expression
by induction of PI3K signaling and repression of TGF-β expres-
sion (Strainic et al., 2013). Second, pTreg differentiation can be
improved by molecules that increase TGF-β signaling (Xu et al.,
2010), like CTLA-4 (Karman et al., 2012). Thus, modulating TGF-
β or PI3K signaling in the periphery might represent a promising
approach to tip the balance in favor of pTreg.
Of importance, TGF-β has a dual and opposite role in the
immune system: it participates not only in the generation of
pTregs, but also, in conjunction with IL-6 or IL-4, induces the dif-
ferentiation of pro-inflammatory Th17 cells or Th9 cells, respec-
tively (Jabeen and Kaplan, 2012; Maddur et al., 2012). Con-
sequently, TGF-β administration could aggravate inflammation
and autoimmunity. Moreover, TGF-β pleiotropic effects outside
the immune system and toxicity limit its therapeutic application
(Flanders and Roberts, 2001) and systemic administration of TGF-
β has been rapidly abandoned by the pharmaceutical industry
(Prud’Homme, 2007).
IL-2 SIGNALING IS MANDATORY FOR pTreg DIFFERENTIATION,
HOMEOSTASIS AND STABILITY
Although IL-2 by itself is not sufficient to generate pTregs,
it seems to be critical for the development of functional
CD4+CD25+Foxp3+ pTregs induced by TGF-β (Chen et al., 2003;
Davidson et al., 2007; Zheng et al., 2007). Indeed, addition of
a neutralizing anti-IL-2 antibody to the culture strikingly abol-
ishes the induction of Foxp3, and IL-2−/− or Stat5−/− naïve T
cells are unable to generate pTregs (Davidson et al., 2007; Lau-
rence et al., 2007; Yao et al., 2007; Zheng et al., 2007). Inter-
estingly, the role of IL-2 is non-redundant, as other common
gamma chain receptor using cytokines cannot restore pTreg gen-
eration in IL-2−/− T cells (Davidson et al., 2007; Zheng et al.,
2007). Likewise, the group of D. Horwitz reported that IL-2 also
potentiates pTreg suppressive function and expression of key Treg-
signature molecules such as CTLA-4, GITR, and CD122 (Zheng
et al., 2007). Different mechanisms have been proposed to explain
IL-2 action in the TGF-β mediated induction system: sustained
Foxp3 expression via JAK3/STAT5 signaling (Chen et al., 2011),
enhancement of proliferation and survival of newly generated
pTregs, or increased conversion of latent to active TGF-β via the
urokinase receptor pathway (Nykjaer et al., 1994; Odekon et al.,
1994).
In the case of lymphopenic recipients, the generation of pTregs
upon transfer of naive T cells seems dependent on IL-2 produc-
tion by activated T cells (Knoechel et al., 2005). Along these lines,
low-dose IL-2 injection into irradiated recipients of allogeneic T
cells increases the generation of donor-derived pTregs (Shin et al.,
2011). However, the specific contribution of tTregs and pTregs to
the Treg increase induced by exogenous IL-2 administration to
lympho-replete mice is still unexplored (Tang et al., 2008; Webster
et al., 2009; Grinberg-Bleyer et al., 2010a).
In vitro and in vivo recently differentiated pTregs present unsta-
ble Foxp3 expression (Floess et al., 2007; Miyao et al., 2012),
which can be lost in an inflammatory context, giving rise to “ex-
Tregs” producing pro-inflammatory cytokines (Zhou et al., 2009).
Importantly, in most of the studies describing Foxp3 instability,
Tregs were put in an environment lacking IL-2 (Tang et al., 2008;
Duarte et al., 2009; Oldenhove et al., 2009; Zhou et al., 2009). How-
ever, IL-2 administration could prevent the conversion of Tregs
(Tang et al., 2008; Duarte et al., 2009; Oldenhove et al., 2009; Zhou
et al., 2009). Furthermore, unstable pTregs are exclusively located
in the CD4+CD25−Foxp3low compartment and, upon time and
“education,” they acquire increased CD25 and Foxp3 expression
as well as a demethylated CNS2 – a well known marker of Treg
stability (Floess et al., 2007; Polansky et al., 2008; Komatsu et al.,
2009; Miyao et al., 2012). Also, IL-2 could prevent conversion of
recently differentiated pTregs by the induction and regulation of
GATA-3 expression (Wang et al., 2011; Wohlfert et al., 2011). Taken
together, all these studies suggest that IL-2 plays an important role
in the “education” of pTregs (Figure 2). However, further studies
are required to determine the additional factors involved in the
stability of the Treg lineage.
THE EMERGING ROLE OF TNF-α IN pTreg HOMEOSTASIS AND
FUNCTION
Interestingly, Housley et al. (2011) point out that pTregs, contrary
to tTregs, may not require TNFR-2 expression to suppress in vivo.
However, TGF-β pre-incubation can render tTregs from TNFR-
2−/− mice as efficient as WT cells, suggesting that in this study,
the implication of TNFR-2 in the suppressive capacity of pTregs
may be hidden by the TGF-β pre-incubation (Housley et al., 2011).
Consequently, the role of TNFR-2 in the suppressive function of
pTregs is still unclear.
In humans, the above-described observation that blocking
TNF-α is associated with an increase of Tregs (Ehrenstein et al.,
2004) can alternatively be explained by the fact that TNF-α expo-
sure could hamper pTreg induction. Indeed, it is not clear whether
the accumulated Tregs observed after anti-TNF-α treatment are
tTreg or pTreg. Then, it could be possible that TNF-α may have
a negative effect on the induction of pTreg cells that would be
removed during anti-TNF-α administration. Indeed, it was shown
that blocking TNF-α increased susceptibility to Histoplasma capsu-
latum infection and induced a population of CD4+CD25+ T cells
possessing IL-10-dependent suppressive function in mice (Deepe
and Gibbons, 2008). Besides, TNF-α can inhibit TGF-β-driven
pTreg induction from Foxp3− Teffs in an EAE model (Zhang
et al., 2013). Finally, it has been pointed out that soluble TNF-α
and membrane-bound TNF-αmay differently affect the process of
pTreg induction in vitro (Kleijwegt et al., 2010). A better knowledge
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FIGURE 2 | IL-2 favors the generation and increases the stability
of the pTreg phenotype. (A) Activation of a naive conventional T cells
through TCR stimulation and in the presence of TGF-β leads to
generation of unstable pTregs that express moderate levels of Foxp3
and CD25. (B) In the presence of IL-2, pTregs increase the expression
levels of Foxp3 and CD25 and the pTreg phenotype is stabilized. (C)
During inflammation and in the absence of IL-2, the pTregs convert
into “ex-pTregs” that can produce different pro-inflammatory
cytokines, such as IFN-γ or IL-17 depending on the environmental
context.
of the mechanisms ruling expression of TNFR-1 and TNFR-2 on
tTregs and pTregs could help explain potential different effects of
TNF-α on these two cell populations.
CONCLUDING REMARKS
We focused our review on three major cytokines that regu-
late different aspects of Treg biology, namely IL-2, TGF-β, and
TNF-α, because they are of great fundamental and clinical
importance. Indeed, immunotherapies based on a better knowl-
edge of the impact of cytokines on Treg biology are emerging
(Chan and Carter, 2010; Koreth et al., 2011; Saadoun et al.,
2011). However, we need to better understand the division of
labor of pTreg and tTreg in the fine tuning of the immune
response. It is not yet clear if each cell type acts preferen-
tially at different localizations, at different timepoints during
the initiation, expansion, contraction, and memory generation
of the immune response, or has specific targets for suppres-
sion. Also, we need to dissect the specific cytokine require-
ments for tTreg and pTreg generation, homeostasis and function,
which are sometimes distinct and sometimes shared. Only with
that information at hands will the extraordinary promises of
tTregs and pTregs be fully exploited in safe and effective clinical
applications.
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